| Between 18 years et 70 years
- | Country :
- France
- | organs :
- Sein
- | Specialty :
- Chimiothérapie
- Thérapies Ciblées
Extract
Prospective, open-label, randomized study of combination therapy of Myocet® plus cyclophosphamide and trastuzumab versus free doxorubicin plus cyclophosphamide alone, each followed by docetaxel and trastuzumab, in neoadjuvant setting in treatment-naive patients with HER2-positive breast cancer.
Scientific Abstract
en cours d'intégration;